Facebook Instagram Linkedin Youtube

STUDIO

Carlos de Sousa, CEO Ultimovacs

Ultimovacs CEO: “Data could put us at the forefront of cancer...

Ultimovacs has announced positive survival data from the phase II NIPU trial assessing the universal cancer vaccine UV1 in malignant mesothelioma. The company’s CEO...
CLS vd Dan Mogren i korridoren på Medicon Village, Lund

CLS looks forward to further expansion

Sarah Fredriksson, vd, Aqilion

Aqilion on phase I results and potential IPO

Panel at BioStock Life Science Fall Summit 2023

Video from day 2 of BioStock Life Science Fall Summit 2023

Video from day 1 of BioStock Life Science Fall Summit 2023

Load more

RECOMMENDED READING

Carlos de Sousa, CEO Ultimovacs

Ultimovacs CEO: “Data could put us at the forefront of cancer...

Ultimovacs has announced positive survival data from the phase II NIPU trial assessing the...
Toleranzia rapporterar Q2

Scandions CMO: “Our overall survival data are quite impressive”

Scandion Oncologys läkemedelskandidat SCO-101 utvärderas för närvarande i fas II-studien CORIST för behandling av...

Saniona’s CEO: ”Selectivity is the cornerstone of future epilepsy treatments”

Stayble

Stayble Therapeutics shifts focus to phase Ib study in disc herniation 

Cline Scientifics CEO convicted of market manipulation

Cline Scientific’s CEO convicted of market manipulation

WntResearch reports Q3

WntResearch’s CEO: “In a better position than ever”

EVENT

© BioStock 2023